Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reporting framework in the testing of predisposition to common adult solid tumors using next-generation sequencing.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2026

Same author

Colorectal cancer detection using noncontrast CT and deep learning: a multicenter and international cohort study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Present management of gastrointestinal stromal tumors.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2025

Same author

Trends of the use of pegylated granulopoiesis growth factors in clinical practice - single oncology centre experience since 2005.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2025

Same author

The guidelines for clinical practice for carriers of germline mutations in the Lynch syndrome predisposition genes MLH1, MSH2, MSH6, PMS2 and large deletions of EPCAM (4.2024).

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2024

Same author

The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024).

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2024

Search research articles

Related Experiment Video

Updated: May 25, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

[Trabectedin registry].

K Kubácková¹, J Fínek, R Vyzula

¹Fakultní nemocnice v Motole, Praha.

Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti

|January 20, 2012

Summary

This summary is machine-generated.

Trabectedin therapy in routine practice showed limited efficacy for soft tissue sarcomas, with disease progression being the primary reason for treatment termination. The drug demonstrated a manageable safety profile, particularly in leiomyosarcomas and liposarcomas.

More Related Videos

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

Related Experiment Videos

Last Updated: May 25, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

Area of Science:

Oncology
Pharmacology
Epidemiology

Background:

The Yondelis (trabectedin) project aimed to gather epidemiological data on soft tissue sarcoma (STS) patients.
It focused on standard treatments and trabectedin's real-world effectiveness in clinical practice.
The study involved comprehensive cancer care centers in the Czech Republic.

Purpose of the Study:

To assess the epidemiological characteristics of STS patients.
To evaluate the standard treatment procedures for STS.
To determine the outcomes of trabectedin therapy in routine clinical practice.

Main Methods:

Retrospective analysis of 45 STS patients treated with trabectedin.
Trabectedin administered at 1.5 mg/m² every 3 weeks.
Patients received trabectedin as second-line (40%), third-line (35.6%), or fourth-line (34.4%) treatment.

Main Results:

Median treatment cycles were 4; most common adverse events were neutropenia (28.9%) and elevated liver enzymes (26.7%).
Disease progression led to therapy termination in 73.8% of patients.
Overall survival was 11.7 months, progression-free survival was 3 months, with a 6.6% objective response rate.

Conclusions:

Trabectedin is recommended as a second-line palliative treatment for STS, especially liposarcomas and leiomyosarcomas.
The drug exhibits a good safety profile in this patient population.
Real-world data supports trabectedin's role in specific STS subtypes.